Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
This clinical trial evaluating bendamustine hydrochloride for chronic lymphocytic leukemia in adult Filipino patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy [Phase 2]
A Phase 2 clinical trial evaluating monoclonal antibody therapy or biological therapy in patients with chronic lymphocytic leukemia or multi…
-
CLINICAL_TRIALS withdrawal · 2015-06-04Clinical Trial Update: Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial of lenalidomide for high-risk chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial of BL22 immunotoxin in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-21Clinical Trial Update: HuMax-CD20 in Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
This clinical trial update indicates that the Phase 1/Phase 2 study of HuMax-CD20 (ofatumumab) for Chronic Lymphocytic Leukemia has been wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment [Phase 2]
A Phase 2 trial of fludarabine phosphate, rituximab, and bevacizumab in relapsed or refractory B-cell chronic lymphocytic leukemia has been …
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment [Phase 2]
A Phase 2 trial of bendamustine plus rituximab for B-cell chronic lymphocytic leukemia that has not responded to prior treatment has been wi…
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant [Phase 2]
Phase 2 trial of lenalidomide with or without rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after au…
-
CLINICAL_TRIALS withdrawal · 2014-01-13Clinical Trial Update: Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 trial evaluating Azadirachta Indica for chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-22Clinical Trial Update: Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 study of dasatinib in combination with bendamustine for Chronic Lymphocytic Leukemia has been withdrawn. The sponsor was Bristol-M…
-
CLINICAL_TRIALS withdrawal · 2012-10-10Clinical Trial Update: Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial of arsenic trioxide for refractory or relapsed chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-09-07Clinical Trial Update: A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia [Phase 2]
Phase 2, single-arm, open-label study evaluating GS-1101 (CAL-101) for previously treated chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-08-03Clinical Trial Update: Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
This document reports the withdrawal of a Phase 1/2 trial evaluating a trivalent influenza vaccine combined with recombinant interferon alph…
-
CLINICAL_TRIALS withdrawal · 2012-08-01Clinical Trial Update: Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) [Phase 1]
A Phase 1 study of oral clofarabine for chronic lymphocytic leukemia has been withdrawn (sponsored by MD Anderson Cancer Center).
-
CLINICAL_TRIALS withdrawal · 2012-05-21Clinical Trial Update: Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells [Phase 1]
Phase 1 trial of autologous tumor cells engineered to express human IL-2 and CD40 ligand for chronic lymphocytic leukemia. The study has bee…
-
CLINICAL_TRIALS withdrawal · 2012-05-03Clinical Trial Update: Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial of cyclophosphamide and rituximab followed by vaccine therapy for chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-01-25Clinical Trial Update: Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1B open-label dose-ranging study of the oral agent AFX-2 in adults with chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-01-11Clinical Trial Update: Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase 2 trial of Bendamustine plus Rituximab in adults aged 65 and older with Chronic Lymphocytic Leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2011-12-30Clinical Trial Update: R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial of R-CHOP plus alemtuzumab for chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2011-12-05Clinical Trial Update: RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial [Phase 2]
This clinical trial update notes termination of the RESPeCT study evaluating lenalidomide (Revlimid) in early-stage poor prognosis chronic l…
-
CLINICAL_TRIALS withdrawal · 2011-07-20Clinical Trial Update: PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab [Phase 2]
Phase 2 trial evaluating the combination of bendamustine and ofatumumab in relapsed/refractory chronic lymphocytic leukemia has been withdra…
-
CLINICAL_TRIALS withdrawal · 2010-04-22Clinical Trial Update: Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma [Phase 1]
A Phase 1 study of MDX-1411 for relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma has been withdrawn from the trial p…
-
CLINICAL_TRIALS withdrawal · 2010-02-26Clinical Trial Update: Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen [Phase 2]
The Phase 2 study of ABT-263 (navitoclax) in B-cell chronic lymphocytic leukemia that failed prior regimens has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-11-05Clinical Trial Update: Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]
The Phase 2 study of CX-3543 in relapsed or refractory B-cell chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-09-05Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]
This document reports that the Phase 1/2 study of MEDI-538 for chronic lymphocytic leukemia has been withdrawn. The sponsor is MedImmune LLC…